Skip to content
Riskpilot
← Back to search
Sign in
Get full access
Cymab ApS
APS
Active
CVR 39859173
Ole Maaløes Vej 3, 2200
København N
Manufacture of pharmaceutical preparations
·
NACE 2120
Est. 2018 · 7 years old
2 employees
Monitor
Share
Denmark
/
Companies
/
Manufacture of pharmaceutical preparations
/
Cymab ApS
Overview
Financials
People & ownership
Related companies
Loading company…
People & ownership
Management
Actively employed in the business
Name
Role
Member since
Current (1)
JH
Johan Henrik Faber
Chief Executive Officer
Chief Executive Officer
2023
Former (3)
AR
Anne Reker Cordt
Management
Management
2024 – 2026
SL
Stine Louise Reedtz Kjellev
Management
Management
2023 – 2024
KF
Kurt Flemming Holmsted
Management
Management
2018 – 2019
Board of directors
Non-executive oversight
Name
Role
Member since
Current (4)
SE
Søren Erik Bjørn
Board of Directors
Board of Directors
2020
TD
Thomas Dal Stenfeldt Batchelor
Board of Directors
Board of Directors
2023
HH
Hans Heugh Wandall
Chairman
Chairman
2023
MN
Mads Nikolaj Behrndt-Eriksen
Board of Directors
Board of Directors
2023
Former (1)
KS
Kim Stengaard Holmsted
Chairman
Chairman
2018 – 2020
Shareholders
As of last annual report
100%
Shareholder
Type
Ownership
Votes
Since
Ebumab Holding ApS
Company
100%
100%
2018
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
More on Cymab ApS
Overview →
Headline figures, risk assessment and company summary
Financials & key figures →
Revenue, EBITDA, balance sheet and 5-year trend
Related companies →
Corporate hierarchy, parent and subsidiary network